iRhythm Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2021. The filing identifies the registrant as iRhythm Technologies, Inc.
Business context
iRhythm provides ambulatory cardiac monitoring services, primarily through its Zio XT and Zio AT wearable monitors and associated data analysis and reporting. Substantially all revenue is generated in the United States. Patient registrations increased in the first half of 2021 as activity recovered, but management cautioned that reopening-related demand may not be sustainable.
Key financial metrics
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $81.3 million | $50.9 million | $155.6 million | $114.4 million |
| Gross profit | $55.3 million | $35.4 million | $106.1 million | $82.9 million |
| Gross margin | 68% | 70% | 68% | 72% |
| Operating loss | $17.0 million | $20.2 million | $44.5 million | $29.3 million |
| Net loss | $17.4 million | $20.4 million | $45.1 million | $29.5 million |
| Net loss per share | $0.59 | $0.75 | $1.54 | $1.09 |
- Cash flow: First-half operating cash use was $42.4 million, versus $32.5 million in the prior-year period. Investing activities provided $118.7 million, mainly from investment maturities; financing activities used $26.1 million.
- Liquidity: At June 30, cash and cash equivalents were $138.9 million and short-term investments were $116.8 million, totaling approximately $255.7 million. Management said liquidity was adequate for the next 12 months and to manage reimbursement-related collection delays.
- Debt: Debt carrying value was $27.2 million, including $11.7 million current and $15.5 million noncurrent. No revolving-credit borrowings were outstanding, and the company reported compliance with loan covenants.
- Balance sheet: Accounts receivable rose to $63.4 million from $29.9 million at year-end 2020; management linked cash-flow pressure in part to delayed claim submissions and reimbursements. Accumulated deficit was $349.8 million.
Material changes versus prior period
- Q2 revenue increased 60%, primarily from higher Zio service volume and improved payor adjudications. First-half revenue increased 36%.
- Gross margin declined to 68% from 70% in Q2 and 72% for the first half. The company cited lower Novitas Medicare reimbursement, capacity-related costs, and other operating costs, partly offset by volume benefits and improved adjudications.
- Q2 net loss narrowed year over year, but first-half net loss widened, reflecting higher operating expenses, particularly selling, general and administrative expense. First-half SG&A rose 45% to $132.5 million; stock-based compensation was $30.5 million versus $10.1 million in the prior-year period.
- CMS represented 14% of first-half revenue, down from 27% a year earlier; contracted commercial payors represented approximately 62%, up from 51%.
Outlook, risks and unusual items
- Medicare reimbursement: Novitas published updated 2021 rates of $103 and $115 for codes 93243 and 93247, respectively, retroactive to January 1. The company said the rates remained significantly below historical Medicare rates and might not cover service costs. The 2022 CMS proposed rule continued contractor pricing for the relevant codes rather than establishing national rates. Failure to improve reimbursement could materially harm revenue, margins, cash flows and financial condition; the filing says this could raise substantial doubt about the company’s ability to continue as a going concern if rates remain below cost and revenue or cost reductions are inadequate.
- Claims and collections: Most first- and second-quarter Zio XT claims held during the CPT-code transition were submitted by quarter-end. Delayed payor reimbursements could pressure second-half cash flows and affect revenue recognition and bad-debt expense.
- COVID-19 and capacity: Registrations recovered, but management warned that the trend may not persist. Pandemic effects may continue to disrupt customer access, operations, supply, staffing and demand. Clinical capacity constraints also limited revenue recognition.
- Profitability and investment: The company expects continued losses and further spending on sales capacity, product development and operations. It planned to complete a manufacturing-facility build-out in the second half of 2021 and expected an additional $3.0 million Verily milestone-related expense for full-year 2021; no payment-triggering milestone was achieved in the first half.
- Controls: Disclosure controls and internal control over financial reporting were not effective at June 30 due to an ongoing material weakness in the control environment. The weakness had previously contributed to misstatements and revisions of earlier financial statements. Management was pursuing remediation, with a stated goal of remediation by December 31, 2021.
- Legal and governance matters: A securities class action was amended on August 2, 2021 to add former and interim CEOs as defendants; the company said it would vigorously defend the case. The company also received a U.S. Attorney’s Office subpoena seeking information about FDA communications and products; it said it was cooperating and had not been informed that it was a target. The filing noted recent executive turnover, including the interim CEO/CFO role held by Douglas J. Devine.
Important facts for investors to verify
- Progress and outcomes of negotiations with Novitas and other Medicare contractors, including whether reimbursement exceeds the cost of providing Zio XT.
- Collection timing and recoverability of the increased accounts receivable balance and the effect of held claims on revenue, bad-debt expense and cash flows.
- Whether patient-registration growth, clinical capacity and gross margins improve or weaken in subsequent periods.
- Remediation of the material weakness and sustained effectiveness of financial-reporting controls.
- Developments in the securities litigation and the U.S. Attorney’s Office investigation, as well as any resulting financial or operational impact.
- Ongoing cash burn, debt amortization, manufacturing expansion costs and the company’s ability to maintain adequate liquidity.